CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

19-386/S018

Trade Name: Brevibloc Injection

Generic Name: Esmolol Hydrochloride

Sponsor: Baxter Pharmaceutical Products Inc.

Approval Date: February 16, 2001

Indications: Short-Term control of heart rate in patients with abnormally fast heart rhythms such as artrial fibrillation, atrial flutter or sinus tachycardia.

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

19-386/S018

CONTENTS

Reviews / Information Included in this NDA Review.	
Approval Letter	X
Approvable Letter	X
Labeling	
Medical Review(s)	
Chemistry Review(s)	X
Pharmacology Review(s)	
Statistical Review(s)	
Microbiology Review(s)	X
Clinical Pharmacology/ Biopharmaceutics Review(s)	
Administrative/Correspondence Document(s)	X

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

19-386/S018

APPROVAL LETTER

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

NDA 19-386/S-018

Baxter Pharmaceutical Products, Inc.
Attention: Ms. Priya Jambhekar
95 Spring Street
New Providence, NJ 07974

Dear Ms. Jambhekar:

Please refer to your supplemental new drug application dated August 30, 2000, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Brevibloc Premixed Injection (esmolol HCl in sodium chloride) in 2500 mg/250mL IntraVia Containers.

We acknowledge receipt of your submissions dated January 12, and February 2 and 9, 2001. Your submission of January 12, 2001 constituted a complete response to our December 29, 2000 action letter.

This supplemental new drug application provides for a premixed injection packaged in 250 mL IntraVia containers (made of PL 2408 plastic bags with laminated foil over-pouch) containing two ports. In addition, the word, "Injection" has been replaced with, "Concentrate" on the Ampul Label with Flag and the Ampuls Tray Label and the phrase, "Ready-to-Use" has been added to the Vial Label and Vials Tray Carton.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the final printed labeling for the IntraVia Containers (package insert and immediate container labels) included in your January 12, 2001 submission and the vial and ampul immediate container labels included in your February 2, 2001 submission. Accordingly, the supplemental application is approved effective on the date of this letter.

When you make your production quantities of the labels, please change, "sodium acetate" to "sodium acetate trihydrate" on the Ampuls Tray Label and, to be consistent, add the amounts of the inactive ingredients to the labels that do not have them already.

We remind you of your postmarketing study commitments in your submissions dated January 12 and February 9, 2001. These commitments are listed below.

1. Baxter PPI makes a post-approval commitment to re-evaluate the subject formulation either to eliminate or significantly reduce overage of esmolol HCl added in the formulation and submit it as a supplement. The detailed plans of action for this commitment will be submitted by August 2001 for the Brevibloc Premixed and Brevibloc Injection and February 2002 for the Brevibloc Concentrate. At the time you submit your plans, please include a date that the supplement(s) will be submitted.

2. Baxter will tentatively reduce the specifications of ——— in the drug product specifications from ———— Baxter PPI will finalize these specifications after reviewing the 24 month stability data that will be available by August 2002.

Submit clinical protocols to your IND for this product. Submit nonclinical and chemistry, manufacturing, and controls protocols and all study final reports to this NDA. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii), you should include a status summary of each commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies, number of patients entered into each study. All submissions, including supplements, relating to these postmarketing study commitments must be prominently labeled **"Postmarketing Study Protocol", "Postmarketing Study Final Report", or "Postmarketing Study Correspondence."**

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.